NIRVF (Nirvana Life Sciences) Debt-to-Equity: -0.20 (As of Jan. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Nirvana Life Sciences Debt-to-Equity?

Nirvana Life Sciences NIRVF Debt-to-Equity is -0.20 as of Jan. 2026. The stock has 3 warning signs investors should review. Among 960 Biotechnology companies, Nirvana Life Sciences ranks worse than 104166.56% on this metric.

Nirvana Life Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2026 was $0.10 Mil. Nirvana Life Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2026 was $0.00 Mil. Nirvana Life Sciences's Total Stockholders Equity for the quarter that ended in Jan. 2026 was $-0.51 Mil. Nirvana Life Sciences's debt to equity for the quarter that ended in Jan. 2026 was -0.20.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Nirvana Life Sciences's Debt-to-Equity or its related term are showing as below:

NIRVF' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.44   Med: -0.06   Max: -0.01
Current: -0.2

During the past 8 years, the highest Debt-to-Equity Ratio of Nirvana Life Sciences was -0.01. The lowest was -0.44. And the median was -0.06.

NIRVF's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.155 vs NIRVF: -0.20

Nirvana Life Sciences  (OTCPK:NIRVF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Nirvana Life Sciences Debt-to-Equity Related Terms

Nirvana Life Sciences Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Nirvana Life Sciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nirvana Life Sciences Debt-to-Equity Chart

Nirvana Life Sciences Annual Data
Trend Oct18 Oct19 Oct20 Oct21 Apr22 Apr23 Apr24 Apr25
Debt-to-Equity
Get a 7-Day Free Trial -0.08 0.00 -0.06 -0.02 -0.07

Nirvana Life Sciences Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.07 -0.07 -0.20 -0.08 -0.20

NIRVF vs VRTX, REGN, RVMD: Debt-to-Equity Comparison

For the Biotechnology subindustry, Nirvana Life Sciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nirvana Life Sciences Debt-to-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nirvana Life Sciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Nirvana Life Sciences's Debt-to-Equity falls into.


Nirvana Life Sciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Nirvana Life Sciences's Debt to Equity Ratio for the fiscal year that ended in Apr. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.071 + 0) / -1.061
=-0.07

Nirvana Life Sciences's Debt to Equity Ratio for the quarter that ended in Jan. 2026 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.103 + 0) / -0.511
=-0.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of -0.20 mean?
Nirvana Life Sciences (NIRVF) has a Debt-to-Equity of -0.20 as of Jan. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Nirvana Life Sciences and its competitors. According to the industry distribution chart, Nirvana Life Sciences ranks #999999 out of 960 companies in the Biotechnology industry.
Is Nirvana Life Sciences' Debt-to-Equity too high?
Nirvana Life Sciences' current Debt-to-Equity is -0.20. Based on the distribution chart, Nirvana Life Sciences ranks #999999 out of 960 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Nirvana Life Sciences' Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nirvana Life Sciences ranks #999999 out of 960 companies for Debt-to-Equity. This places Nirvana Life Sciences in the lower half of its industry. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Nirvana Life Sciences and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nirvana Life Sciences's current Debt-to-Equity is -0.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nirvana Life Sciences stock overvalued right now?
Nirvana Life Sciences (NIRVF) has a current Debt-to-Equity of -0.20. The current Debt-to-Equity is -0.20. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Nirvana Life Sciences (NIRVF), the current Debt-to-Equity is -0.20 as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nirvana Life Sciences Business Description

Other Exchanges NIRV.X:Canada
Address 650 West Georgia Street, Suite 2110, Vancouver, BC, CAN, V6B 4N8
Nirvana Life Sciences Inc is a Canada-based company, which is engaged in the scientific research and development of therapeutic products derived from psychedelics. The Company is also focused on developing methodologies for standardized, quality-controlled extraction and purification of psychoactive compounds. The Company operates in a single reportable segment: research and development of therapeutic products derived from psychedelics. The company is working on novel formulations of psilocybin and other naturally-sourced psychedelics to treat pain, opioid dependency, and other health problems.